UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
September 28, 2018
(
September 25, 2018)
Heyu Biological Technology Corporation
(Exact Name of Registrant as Specified in its Charter)
Nevada
|
|
000-26731
|
|
87-0627910
|
(State or Other Jurisdiction of
Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
4th Floor, No. 10 Building, Xinglin Bay Business Operation Center,
Jimei District, Xiamen City,
Fujian Province, China 361022
(Address of Principal Executive Offices, Zip Code)
Registrant’s telephone number, including area code: (86) 158 5924 0902
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Item 8.01 Other Events.
Heyu Biological Technology Corporation (the “Company”) previously approved a forward split of its issued and outstanding shares of common stock (the "Forward Split") on a 100 for 1 basis, the effect of which increased the number of shares of common stock issued and outstanding from 10,322,660 to 1,032,266,000 on September 25, 2018 (the “Effective Date”).
On September 25, 2018, the Financial Industry Regulatory Authority, Inc. (the "FINRA") announced the Forward Split with an Effective Date of September 25, 2018 and a Pay Date of September 24, 2018. In connection with the Forward Split, no fractional shares are necessary to be issued, and stockholders do not need to present certificates for exchange. The Forward Split will be payable directly to each stockholder by the issuance of shares representing the split differential.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
Heyu Biological Technology Corporation
|
|
|
|
|
By:
|
_
/s/Ban Siong Ang
_________
|
Name:
|
Ban Siong Ang
|
Title:
|
Chief Executive Officer
|
|
|
Dated:
|
September 28, 2018
|